SCHEMBL256855

SCHEMBL256855

COc1c(C)cccc1C(=O)Cc1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
HIF1A Q16665 3/20 0.52
CNR2 P34972 1/20 0.48
TP53 P04637 2/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 5/20 0.47
MAPT P10636 3/20 0.47
HTT P42858 2/20 0.47
MAPK1 P28482 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
XBP1 P17861 1/20 0.44
ATM Q13315 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 1/20 0.42
HTR2A P28223 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL256823 0.83 LMNA (0.50) SMN1; SMN2NPC1RAB9AHIF1ACNR2
SCHEMBL8800692 0.78 USP2 (0.52) SMN1; SMN2NPC1RAB9AHIF1ATP53
SCHEMBL15100733 0.77 KDM4E (0.48) SMN1; SMN2NPC1RAB9ACNR2LMNA
SCHEMBL10955656 0.77 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9AHIF1ACNR2
SCHEMBL9720578 0.76 ALDH1A1 (0.47) SMN1; SMN2NPC1RAB9ALMNAMAPT
SCHEMBL1276013 0.76 NPC1 (0.60) SMN1; SMN2NPC1RAB9AHIF1ATP53
SCHEMBL19442276 0.73 MAPT (0.59) SMN1; SMN2NPC1RAB9ATP53USP2
SCHEMBL28799843 0.73 LMNA (0.54) SMN1; SMN2NPC1RAB9AHIF1ACNR2
SCHEMBL15902289 0.72 BRPF1 (0.61) SMN1; SMN2RAB9AHIF1ACNR2TP53
SCHEMBL9726590 0.71 KDM4E (0.52) SMN1; SMN2NPC1RAB9AHIF1AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 SMN1; SMN2 2704/4885NPC1 1990/4885RAB9A 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.